211 related articles for article (PubMed ID: 38676793)
1. Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery.
Weng T; Jenkins BJ; Saad MI
Methods Mol Biol; 2024; 2806():19-30. PubMed ID: 38676793
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
[TBL] [Abstract][Full Text] [Related]
3. Patient-Derived Xenografts: Historical Evolution, Immunocompromised Host Models, and Translational Significance.
Thompson J; Saad MI
Methods Mol Biol; 2024; 2806():1-8. PubMed ID: 38676791
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
Powley IR; Patel M; Miles G; Pringle H; Howells L; Thomas A; Kettleborough C; Bryans J; Hammonds T; MacFarlane M; Pritchard C
Br J Cancer; 2020 Mar; 122(6):735-744. PubMed ID: 31894140
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
6. Challenges with biomarkers in cancer drug discovery and development.
Ileana Dumbrava E; Meric-Bernstam F; Yap TA
Expert Opin Drug Discov; 2018 Aug; 13(8):685-690. PubMed ID: 29792354
[No Abstract] [Full Text] [Related]
7. Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments.
Zarzosa P; Navarro N; Giralt I; Molist C; Almazán-Moga A; Vidal I; Soriano A; Segura MF; Hladun R; Villanueva A; Gallego S; Roma J
Clin Transl Oncol; 2017 Jan; 19(1):44-50. PubMed ID: 27718156
[TBL] [Abstract][Full Text] [Related]
8. Development and Expansion of Patient-Derived Xenografts for Endometrial Cancer.
Sengal AT; Pollock PM
Methods Mol Biol; 2024; 2806():101-115. PubMed ID: 38676799
[TBL] [Abstract][Full Text] [Related]
9. Zebrafish Xenografts for Drug Discovery and Personalized Medicine.
Xiao J; Glasgow E; Agarwal S
Trends Cancer; 2020 Jul; 6(7):569-579. PubMed ID: 32312681
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenografts as tools in pharmaceutical development.
Izumchenko E; Meir J; Bedi A; Wysocki PT; Hoque MO; Sidransky D
Clin Pharmacol Ther; 2016 Jun; 99(6):612-21. PubMed ID: 26874468
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
Lee JY; Kim SY; Park C; Kim NK; Jang J; Park K; Yi JH; Hong M; Ahn T; Rath O; Schueler J; Kim ST; Do IG; Lee S; Park SH; Ji YI; Kim D; Park JO; Park YS; Kang WK; Kim KM; Park WY; Lim HY; Lee J
Oncotarget; 2015 Sep; 6(28):25619-30. PubMed ID: 26296973
[TBL] [Abstract][Full Text] [Related]
12. Fidelity of a PDX-CR model for bladder cancer.
Mondal AM; Ma AH; Li G; Krawczyk E; Yuan R; Lu J; Schlegel R; Stamatakis L; Kowalczyk KJ; Philips GK; Pan CX; Liu X
Biochem Biophys Res Commun; 2019 Sep; 517(1):49-56. PubMed ID: 31303270
[TBL] [Abstract][Full Text] [Related]
13. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived xenografts as preclinical neuroblastoma models.
Braekeveldt N; Bexell D
Cell Tissue Res; 2018 May; 372(2):233-243. PubMed ID: 28924803
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived tumour xenografts for breast cancer drug discovery.
Cassidy JW; Batra AS; Greenwood W; Bruna A
Endocr Relat Cancer; 2016 Dec; 23(12):T259-T270. PubMed ID: 27702751
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived tumor xenograft models for melanoma drug discovery.
Harris AL; Joseph RW; Copland JA
Expert Opin Drug Discov; 2016 Sep; 11(9):895-906. PubMed ID: 27454070
[TBL] [Abstract][Full Text] [Related]
18. Molecular and clinical implementations of ovarian cancer mouse avatar models.
Zayed AA; Mandrekar SJ; Haluska P
Chin Clin Oncol; 2015 Sep; 4(3):30. PubMed ID: 26408297
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived xenografts (PDXs) as model systems for human cancer.
Invrea F; Rovito R; Torchiaro E; Petti C; Isella C; Medico E
Curr Opin Biotechnol; 2020 Jun; 63():151-156. PubMed ID: 32070860
[TBL] [Abstract][Full Text] [Related]
20. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
